Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Capital Employed (2016 - 2025)

Cardiff Oncology's Return on Capital Employed history spans 14 years, with the latest figure at 1.05% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 32.0% year-over-year to 1.05%; the TTM value through Dec 2025 reached 1.05%, down 32.0%, while the annual FY2025 figure was 0.78%, 14.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 1.05% at Cardiff Oncology, down from 0.98% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.16% in Q1 2021 and bottomed at 1.05% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 0.4% (2023), against an average of 0.53%.
  • The largest annual shift saw Return on Capital Employed surged 206bps in 2021 before it crashed -32bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.21% in 2021, then crashed by -71bps to 0.36% in 2022, then crashed by -71bps to 0.61% in 2023, then decreased by -20bps to 0.73% in 2024, then crashed by -44bps to 1.05% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Return on Capital Employed are 1.05% (Q4 2025), 0.98% (Q3 2025), and 0.85% (Q2 2025).